TRIB Stock Overview
Acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Trinity Biotech plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.80 |
| 52 Week High | US$3.55 |
| 52 Week Low | US$0.75 |
| Beta | 0.97 |
| 1 Month Change | -34.43% |
| 3 Month Change | -36.00% |
| 1 Year Change | -60.49% |
| 3 Year Change | -89.87% |
| 5 Year Change | -84.91% |
| Change since IPO | -99.00% |
Recent News & Updates
Recent updates
Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding
Sep 25
A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb
Aug 07The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More
Jun 11Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%
Mar 02Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry
Dec 18A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)
Sep 12Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?
Aug 08Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price
Jun 09Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)
Apr 23This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts
Apr 23Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?
Mar 01Trinity Biotech appoints former GE executive Aris Kekedjian as CEO
Oct 03At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?
Sep 01Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M
Jun 30Shareholder Returns
| TRIB | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -11.6% | -1.5% | -2.4% |
| 1Y | -60.5% | 10.0% | 23.4% |
Return vs Industry: TRIB underperformed the US Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: TRIB underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| TRIB volatility | |
|---|---|
| TRIB Average Weekly Movement | 14.1% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TRIB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TRIB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 380 | John Gillard | www.trinitybiotech.com |
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren’s syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders.
Trinity Biotech plc Fundamentals Summary
| TRIB fundamental statistics | |
|---|---|
| Market cap | US$7.57m |
| Earnings (TTM) | -US$20.33m |
| Revenue (TTM) | US$59.13m |
0.1x
P/S Ratio-0.4x
P/E RatioIs TRIB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRIB income statement (TTM) | |
|---|---|
| Revenue | US$59.13m |
| Cost of Revenue | US$38.00m |
| Gross Profit | US$21.13m |
| Other Expenses | US$41.46m |
| Earnings | -US$20.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.15 |
| Gross Margin | 35.74% |
| Net Profit Margin | -34.39% |
| Debt/Equity Ratio | -310.7% |
How did TRIB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 04:15 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Trinity Biotech plc is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura McGuigan | B. Riley Securities, Inc. |
| Lawrence Solow | CJS Securities, Inc. |
| William Bonello | Craig-Hallum Capital Group LLC |